Listen to Gynecologic Oncology
by Gynecologic Oncology
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇵🇭PH · Science#189500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 ~2x weekly·67 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇵🇭100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Sep 1, 2026
31m 57s
ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know
Jul 31, 2026
26m 32s
Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Jul 29, 2026
25m 53s
Cologuard-like test for identification of endometrial cancer through vaginal sampling
May 13, 2026
25m 41s
PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast
May 8, 2026
19m 50s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 9/1/26 |  FIGO 2023 Upstaging: Overtreatment or Overdue Precision? | Editor's Choice: FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer Editorial: A path to precision in endometrial cancer management: Moving past FIGO 2023 Hosted by: David Gaffney, MD, PhD The University of Utah, Salt Lake City, Utah, United States of America Featuring: Allison Roy, MD SUNY Upstate Medical University, Syracuse, NY, United States of America Jessica N. McAlpine University of British Columbia, Vancouver, BC, Canada David Mu... | 31m 57s | ||||||
| 7/31/26 |  ERAS 2026: Key Updates Every Gynecologic Oncologist Should Know | Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update Editorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelines Hosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA Featuring: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, Universi... | 26m 32s | ||||||
| 7/29/26 |  Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer | Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer Hosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA Featuring: Kathleen Moore, M... | 25m 53s | ||||||
| 5/13/26 |  Cologuard-like test for identification of endometrial cancer through vaginal sampling | Editor's Choice: Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding Editorial: Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice Hosted by: Charles N. Landen Jr., MD; University of Virginia Charlottesville, VA, USA Featuring: Jamie N. Bakkum-Gamez, MD; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA John B. Kisiel, MD; Division... | 25m 41s | ||||||
| 5/8/26 | PARP Inhibitors in Ovarian Cancer: A Society of Gynecologic Oncology Podcast | Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review Moderator: Ursula A. Matulonis, MD; Dana-Farber Cancer Institute Speakers: Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone Health Róisín E. O’Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical College Yvett... | 19m 50s | ||||||
| 4/9/26 |  Home the Same Day? Testing the Limits in Ovarian Cancer Debulking Surgery | Editor's Choice: Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer Editorial: Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection Hosted by: Gregg Nelson, MD, PhD, FRCSC University of Calgary, Calgary, Alberta Canada Featuring: Surabhi Tewari, MD, Department of Obstetrics and Gynecology, Mass General Brigham, Harvard Medical School, Boston, MA, USA Alexander Melamed, MD... | 18m 21s | ||||||
| 3/16/26 |  Recognizing and Managing ADC-Associated Pulmonary Toxicities | Editor’s Choice: Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement Hosted by: Jose Alejandro Rauh-Hain, MD MPH Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Featuring: Charles A. Powell, MD, MBA Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA Check out more... | 29m 40s | ||||||
| 2/1/26 |  In good SHAPE | Editor's Choice: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial Editorial: Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cance... | 23m 45s | ||||||
| 1/1/26 |  ctDNA-Guided PARPi Therapy in Ovarian Cancer | Editor’s Choice: Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Editorial: Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Rebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USA Christina M. Annunziata, American Cancer Society, Atlanta, GA, USA Check out more content on the ... | 25m 21s | ||||||
| 12/1/25 |  Beyond treatment: The who, why, when, where and what of cancer follow up | Editor’s Choice: Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches Editorial: Who is following up? Rethinking survivorship and surveillance Hosted by: Paola A Gehrig, MD University of Virginia Charlottesville, Virginia United States Featuring: Lee-may Chen, MD; Division of Gynecologic Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States Esther Vermaas; Department of Obstetrics and Gynaecology,... | 28m 29s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 11/20/25 | Ovarian Cancer After Breast Cancer in Women with BRCA Variants | Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant Editorial: Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 carriers:Why is this a question? Hosted by: John Farley, MD, COL(ret), FACOG, FACS, St Joseph's Hospital and Medical Center, Phoenix, AZ, United States of America Featuring: Steven Narod, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada Stephanie Blank, Icahn School of Medic... | 28m 31s | ||||||
| 11/17/25 | Making a difference: Molecules, mechanisms and more | Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer Editor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer Editorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology Hosted by:... | 38m 54s | ||||||
| 11/6/25 | Navigating Surgical Complexity After Ovarian Cancer Neoadjuvant Chemotherapy | Editor’s Choice: Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA Oliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, German... | 20m 31s | ||||||
| 9/26/25 | Cervical Cancer Care in Focus: Consensus on Quality, Equity, and Radiation Therapy | Editor’s Choice: Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S Editorial: Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment Editorial: Minimum standards for radiat... | 21m 04s | ||||||
| 8/29/25 | Beyond Anesthesia: Self-Hypnosis in ERAS Programs | Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms Hosted by: Jose Alejandro Rauh-Hain, MD, Associate Editor of Gynecologic Oncology Featuring: Larissa Alejandra Meyer, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United ... | 24m 52s | ||||||
| 7/14/25 | Carcinosarcoma Wars: A New Hope for TROP-2 Therapeutic Targeting | Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma Editorial: The search for new therapeutic options for uterine carcinosarcoma Hosted by: Amanda Nickles Fader, MD, Deputy Editor of Gynecologic Oncology Featuring: Britta Weigelt, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Sara Moufarrij, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA Katherin... | 20m 25s | ||||||
| 7/8/25 | To divert or not to divert: that is the question | Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs Editorial: Diverting ileostomy: An ounce of prevention, but when? Hosted by: Diane Yamada, MD, Deputy Editor of Gynecologic Oncology Featuring: Anna Fagotti, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy Virginia Vargiu, Department of Woman and Child Health and Public... | 27m 38s | ||||||
| 5/2/25 | A randomized clinical trial of metformin in endometrial cancer | Editor’s choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study Editorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity Hosted by: Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic Oncology Featuring: V.L. Bae-Jump, Univers... | 17m 26s | ||||||
| 3/26/25 | Understanding the Implications of the Platinum-Free Interval in Endometrial Cancer | Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind? Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic Oncology Featuring: Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics a... | 16m 12s | ||||||
| 3/3/25 | Prophylactic chemotherapy to prevent post-molar gestational trophoblastic disease - a long journey and a remarkable study | Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances? Hosted by: David Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Fea... | 18m 12s | ||||||
| 1/27/25 | Clinical trials: Panacea or pitfall | Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival Editorial: Clinical trials are not the solution to inequities in cancer care Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Ashley Felix, PhD, MPH, Associate Professor, Division of Epidemiology. The Ohio State University College of Public Health David Shalowitz, MD, MSHP, Director for Health Equity and Community Outreach. West Michigan Cancer C... | 30m 47s | ||||||
| 12/30/24 | FOLR1 status: Landscape beyond high grade serous ovarian cancer | Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma Editorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma Hosted by: Warner Huh, MD, Deputy Editor of Gynecologic Oncology Featuring: Tullia Rushton, MD Beryl L. Manning-Geist, MD Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net | 20m 26s | ||||||
| 11/25/24 | Benefits of hormonal therapy for low grade serous ovarian cancer | Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study Editorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief! Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Alexander Melamed, MD Jubilee Brown, MD Check out more content on the journal's homepage at http... | 22m 40s | ||||||
| 10/23/24 | Implementation and impact of a financial navigation program in gynecologic oncology | Editor’s Choice: Implementation of a financial navigation program in gynecologic oncology Editorial: Financial toxicity: moving from describing the problem toward developing interventions Hosted by: Diane Yamada, MD Featuring: Katharine M. Esselen, MD Margaret Liang, MD Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net | 32m 25s | ||||||
| 9/26/24 | LVSI in Stage 1 Endometrial Cancer | Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment? Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology Featuring: Mohamed Elshaikh, MD Beriwal Sushil MD Check out more content on the journal's homepage at https://www.gynecolog... | 18m 19s | ||||||
Showing 25 of 72
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Listen to Gynecologic Oncology
Peaked at #189 in PH, currently #189 in PH.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| PH | — | #189 | #189 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.